XENON PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.8 USD | -0.46% |
|
-4.08% | -15.76% |
Financials (USD)
| Sales 2024 * | 1.76M | Sales 2025 * | 8.84M | Capitalization | 2.93B |
|---|---|---|---|---|---|
| Net income 2024 * | -221M | Net income 2025 * | -262M | EV / Sales 2024 * | 1,248 x |
| Net cash position 2024 * | 727M | Net cash position 2025 * | 650M | EV / Sales 2025 * | 258 x |
| P/E ratio 2024 * |
-13.3
x | P/E ratio 2025 * |
-11.9
x | Employees | 255 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xenon Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | -0.46% | ||
| 1 week | -4.08% | ||
| Current month | -4.55% | ||
| 1 month | -3.02% | ||
| 3 months | -21.22% | ||
| 6 months | +35.05% | ||
| Current year | -15.76% |
1 week
38.51
40.66
1 month
38.5144.37
Current year
38.5150.99
1 year
27.9950.99
3 years
14.6550.99
5 years
7.0050.99
10 years
2.1050.99
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 48 | 13-10-20 |
Simon Pimstone
FOU | Founder | 56 | 96-11-04 |
Sherry Aulin
DFI | Director of Finance/CFO | 40 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 20-11-04 |
Mohammad Azab
BRD | Director/Board Member | 68 | 03-09-30 |
Justin Gover
BRD | Director/Board Member | 53 | 23-08-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 14 M€ | -3.15% | ||
| 0.22% | 0 M€ | 0.00% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.20% | 12 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 38.8 | -0.46% | 418,657 |
| 24-05-21 | 38.98 | -3.56% | 359,807 |
| 24-05-20 | 40.42 | +1.56% | 469,380 |
| 24-05-17 | 39.8 | -1.34% | 261,461 |
| 24-05-16 | 40.34 | -0.27% | 505,234 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotes
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Calendar
2024-06-04
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
38.8
USD
Average target price
57.44
USD
Spread / Average Target
+48.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.76% | 2.93B | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.82% | 21.97B | |
| -4.92% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
- Stock Market
- Equities
- XENE Stock
